ClinicalTrials.gg
CompletedNCT06295796Updated Feb 17, 2026Results posted

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

A Phase 1 interventional study of MK-8527 in Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
25th of 32
18 · median 26
Started
2024
with 1 other
Phase 1
25 of 32
2 open now
Registered
27th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 25th largest by enrollment, is one of 2 that started in 2024, is one of 25 in phase 1, and was the 27th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

Moderate and Severe RI

  • With the exception of RI, is in sufficient health for study participation.
  • Has stable renal function.

Healthy

  • Matches mean age to participants with moderate and severe RI.
  • Has normal renal function.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

All participants

  • History of cancer ().
  • Positive test results for Human-immunodeficiency virus (), surface antigen (HBsAg), or virus (HCV).
  • Had a major surgery or lost significant volume of blood within 56 days prior to dosing.
  • Donated plasma within 7 days prior to dosing.

Moderate and Severe RI

  • Failed renal transplant or had a nephrectomy.
  • End stage renal disease requiring dialysis.
  • Any significant arrhythmia or conduction abnormality.
  • Has non-sustained or sustained ventricular tachycardia.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Moderate Renal Impairment

    Participants with moderate renal impairment receive a single dose of MK-8527 on Day 1.

    Drug: MK-8527

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment receive a single dose of MK-8527 on Day 1.

    Drug: MK-8527

  • Experimental
    Healthy

    Healthy participants receive a single dose of MK-8527 on Day 1.

    Drug: MK-8527

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527 in participant's plasma. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

  2. Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527 in participant's plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

  3. Maximum Concentration (Cmax) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527 in participant's plasma. Cmax was defined as the maximum observed concentration of MK-8527 in plasma after the administration of a given dose.

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

  4. Time to Maximum Concentration (Tmax) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the tmax of MK-8527 in participant's plasma. Tmax of MK-8527 in plasma was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

  5. Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527 in participant's plasma. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

  6. Apparent Clearance (CL/F) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the CL/F of MK-8527 in participant's plasma. CL/F was defined as dose/(AUC0-inf).

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

  7. Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527 in Plasma

    Blood samples were collected at pre-specified time points to determine the Vz/F of MK-8527 in participant's plasma. Vz/F of MK-8527 in plasma was determined using the formula Dose/(AUC0-inf × λz).

    Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose

Secondary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 29 days

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 29 days

  3. AUC0-last of MK-8527-triphosphate (TP) in Peripheral Blood Mononuclear Cells (PBMCs)

    Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration.

    Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose

  4. AUC0-inf of MK-8527-TP in PBMCs

    Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.

    Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose

  5. Cmax of MK-8527-TP in PBMCs

    Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Cmax was defined as the maximum observed concentration of MK-8527-TP after the administration of a given dose.

    Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose

  6. Concentration at 168 Hours (C168) of MK-8527-TP in PBMCs

    Blood samples were collected at pre-specified time points to determine the C168 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C168 of MK-8527-TP in PBMCs was determined.

    Time frame: 168 hours post dose

  7. Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs in Participants With Moderate and Severe Renal Impairment

    Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C672 of MK-8527-TP in PBMCs was determined.

    Time frame: 672 hours post dose

  8. C672 of MK-8527-TP in PBMCs in Healthy Participants

    Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Since ≤ 50% of healthy participants had BLQ values, the BLQ value was set to zero and the median, minimum, and maximum was reported for C672.

    Time frame: 672 hours post dose

  9. Tmax of MK-8527-TP in PBMCs

    Blood samples were collected at pre-specified time points to determine the Tmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Tmax of MK-8527-TP was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration

    Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose

  10. T1/2 of MK-8527-TP in PBMCs

    Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).

    Time frame: Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose

07

Results

Posted Feb 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneHealthyModerate Renal ImpairmentSevere Renal Impairment
Started666
Completed666
Not completed000

Outcome measures

SecondaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 29 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
ParticipantsHealthyModerate Renal ImpairmentSevere Renal Impairment
Number of Participants Who Experience One or More Adverse Events (AEs)000
SecondaryNumber of Participants Who Discontinue Study Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 29 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Due to an AE
ParticipantsHealthyModerate Renal ImpairmentSevere Renal Impairment
Number of Participants Who Discontinue Study Due to an AE000
SecondaryAUC0-last of MK-8527-triphosphate (TP) in Peripheral Blood Mononuclear Cells (PBMCs)

Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration.

Time frame:
Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Reported as:
Geometric mean · pmol*hr/10^6 cells
AUC0-last of MK-8527-triphosphate (TP) in Peripheral Blood Mononuclear Cells (PBMCs)
pmol*hr/10^6 cellsHealthyModerate Renal ImpairmentSevere Renal Impairment
AUC0-last of MK-8527-triphosphate (TP) in Peripheral Blood Mononuclear Cells (PBMCs)217 ± 37.2493 ± 51.6588 ± 37.6
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 2.26 · 90% CI 1.44 to 3.56GMR=Moderate RI (test)/Healthy (reference)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 2.71 · 90% CI 1.85 to 3.95GMR=Severe RI (test)/Healthy (reference)
SecondaryAUC0-inf of MK-8527-TP in PBMCs

Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.

Time frame:
Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Reported as:
Geometric mean · pmol*hr/10^6 cells
AUC0-inf of MK-8527-TP in PBMCs
pmol*hr/10^6 cellsHealthyModerate Renal ImpairmentSevere Renal Impairment
AUC0-inf of MK-8527-TP in PBMCs235 ± 35.9468 ± 27.5552 ± 5.9
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 2.00 · 90% CI 1.42 to 2.81GMR=Moderate RI (test)/Healthy (reference)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 2.35 · 90% CI 1.76 to 3.14GMR=Severe RI (test)/Healthy (reference)
SecondaryCmax of MK-8527-TP in PBMCs

Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Cmax was defined as the maximum observed concentration of MK-8527-TP after the administration of a given dose.

Time frame:
Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Reported as:
Geometric mean · pmol/10^6 cells
Cmax of MK-8527-TP in PBMCs
pmol/10^6 cellsHealthyModerate Renal ImpairmentSevere Renal Impairment
Cmax of MK-8527-TP in PBMCs1.77 ± 28.43.82 ± 78.43.18 ± 14.7
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 2.16 · 90% CI 1.20 to 3.86GMR=Moderate RI (test)/Healthy (reference)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 2.16 · 90% CI 1.20 to 3.86GMR=Severe RI (test)/Healthy (reference)
SecondaryConcentration at 168 Hours (C168) of MK-8527-TP in PBMCs

Blood samples were collected at pre-specified time points to determine the C168 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C168 of MK-8527-TP in PBMCs was determined.

Time frame:
168 hours post dose
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 168 Hours (C168) of MK-8527-TP in PBMCs
pmol/10^6 cellsHealthyModerate Renal ImpairmentSevere Renal Impairment
Concentration at 168 Hours (C168) of MK-8527-TP in PBMCs0.470 ± 39.30.948 ± 118.91.03 ± 46.0
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 2.02 · 90% CI 0.91 to 4.45GMR=Moderate RI (test)/Healthy (reference)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 2.19 · 90% CI 1.42 to 3.36GMR=Severe RI (test)/Healthy (reference)
SecondaryConcentration at 672 Hours (C672) of MK-8527-TP in PBMCs in Participants With Moderate and Severe Renal Impairment

Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Geometric mean of C672 of MK-8527-TP in PBMCs was determined.

Time frame:
672 hours post dose
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs in Participants With Moderate and Severe Renal Impairment
pmol/10^6 cellsHealthyModerate Renal ImpairmentSevere Renal Impairment
Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs in Participants With Moderate and Severe Renal Impairment—0.183 ± 54.10.248 ± 50.7
SecondaryC672 of MK-8527-TP in PBMCs in Healthy Participants

Blood samples were collected at pre-specified time points to determine the C672 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Since ≤ 50% of healthy participants had BLQ values, the BLQ value was set to zero and the median, minimum, and maximum was reported for C672.

Time frame:
672 hours post dose
Reported as:
Median · pmol/10^6 cells
C672 of MK-8527-TP in PBMCs in Healthy Participants
pmol/10^6 cellsHealthyModerate Renal ImpairmentSevere Renal Impairment
C672 of MK-8527-TP in PBMCs in Healthy Participants0.0673 (0.00 to 0.0874)——
SecondaryTmax of MK-8527-TP in PBMCs

Blood samples were collected at pre-specified time points to determine the Tmax of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. Tmax of MK-8527-TP was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration

Time frame:
Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Reported as:
Median · hr
Tmax of MK-8527-TP in PBMCs
hrHealthyModerate Renal ImpairmentSevere Renal Impairment
Tmax of MK-8527-TP in PBMCs23.08 (11.92 to 23.92)23.92 (23.53 to 167.07)23.01 (23.00 to 23.53)
SecondaryT1/2 of MK-8527-TP in PBMCs

Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527-TP, the active triphosphate anabolite of MK-8527, in participant's PBMCs. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).

Time frame:
Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose
Reported as:
Geometric mean · hr
T1/2 of MK-8527-TP in PBMCs
hrHealthyModerate Renal ImpairmentSevere Renal Impairment
T1/2 of MK-8527-TP in PBMCs170 ± 44.1212 ± 24.6251 ± 36.2
PrimaryArea Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the AUC0-last of MK-8527 in participant's plasma. AUC0 to last of MK-8527 was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Geometric mean · nM·hr
Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma
nM·hrHealthyModerate Renal ImpairmentSevere Renal Impairment
Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma769 ± 21.41160 ± 24.61430 ± 20.1
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 1.51 · 90% CI 1.19 to 1.92GMR=Moderate RI (test)/ Healthy (control)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 1.86 · 90% CI 1.50 to 2.31GMR=Severe RI (test)/Healthy (reference)
PrimaryArea Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the AUC0-inf of MK-8527 in participant's plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest,last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Geometric mean · nM·hr
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma
nM·hrHealthyModerate Renal ImpairmentSevere Renal Impairment
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma918 ± 22.21640 ± 30.02060 ± 24.0
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 1.79 · 90% CI 1.36 to 2.36GMR=Moderate RI (test)/Healthy (reference)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 2.24 · 90% CI 1.77 to 2.85GMR=Severe RI (test)/Healthy (reference)
PrimaryMaximum Concentration (Cmax) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the Cmax of MK-8527 in participant's plasma. Cmax was defined as the maximum observed concentration of MK-8527 in plasma after the administration of a given dose.

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Geometric mean · nM
Maximum Concentration (Cmax) of MK-8527 in Plasma
nMHealthyModerate Renal ImpairmentSevere Renal Impairment
Maximum Concentration (Cmax) of MK-8527 in Plasma112 ± 25.7161 ± 48.991.7 ± 22.1
Statistical analysis
  • Healthy vs Moderate Renal Impairment · Geometric mean ratio (gmr): 1.43 · 90% CI 0.96 to 2.14GMR=Moderate RI (test)/Healthy (reference)
  • Healthy vs Severe Renal Impairment · Geometric mean ratio (gmr): 0.82 · 90% CI 0.64 to 1.05GMR= Severe RI (test)/Healthy (reference)
PrimaryTime to Maximum Concentration (Tmax) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the tmax of MK-8527 in participant's plasma. Tmax of MK-8527 in plasma was determined by deriving the difference between the time of the blood draw associated with the Cmax and the time of study drug administration

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Median · hr
Time to Maximum Concentration (Tmax) of MK-8527 in Plasma
hrHealthyModerate Renal ImpairmentSevere Renal Impairment
Time to Maximum Concentration (Tmax) of MK-8527 in Plasma0.75 (0.52 to 1.53)0.75 (0.50 to 1.00)0.99 (0.25 to 6.00)
PrimaryApparent Terminal Half-life (t1/2) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the t1/2 of MK-8527 in participant's plasma. t1/2 was defined as 0.693/Apparent terminal elimination rate constant (λz).

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Geometric mean · hr
Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma
hrHealthyModerate Renal ImpairmentSevere Renal Impairment
Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma84.2 ± 14.1118 ± 32.5113 ± 38.0
PrimaryApparent Clearance (CL/F) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the CL/F of MK-8527 in participant's plasma. CL/F was defined as dose/(AUC0-inf).

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Geometric mean · Liter/hr
Apparent Clearance (CL/F) of MK-8527 in Plasma
Liter/hrHealthyModerate Renal ImpairmentSevere Renal Impairment
Apparent Clearance (CL/F) of MK-8527 in Plasma21.2 ± 22.211.8 ± 30.09.45 ± 24.0
PrimaryApparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527 in Plasma

Blood samples were collected at pre-specified time points to determine the Vz/F of MK-8527 in participant's plasma. Vz/F of MK-8527 in plasma was determined using the formula Dose/(AUC0-inf × λz).

Time frame:
Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527 in Plasma
LiterHealthyModerate Renal ImpairmentSevere Renal Impairment
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527 in Plasma2570 ± 29.72020 ± 27.01540 ± 36.5

Adverse events

Collected over up to approximately 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate Renal Impairment0/6 (0%)0/6 (0%)0/6 (0%)
Severe Renal Impairment0/6 (0%)0/6 (0%)0/6 (0%)
Healthy0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)HealthyModerate Renal ImpairmentSevere Renal ImpairmentTotal
Mean60.0 ± 5.2563.7 ± 6.4467.8 ± 5.8863.8 ± 6.43
Sex: Female, Male
Sex: Female, Male(Participants)HealthyModerate Renal ImpairmentSevere Renal ImpairmentTotal
Female3238
Male34310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HealthyModerate Renal ImpairmentSevere Renal ImpairmentTotal
Hispanic or Latino1001
Not Hispanic or Latino56617
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HealthyModerate Renal ImpairmentSevere Renal ImpairmentTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American34512
White3216
More than one race0000
Unknown or Not Reported0000
Baseline estimated glomerular filtration rate (eGFR)
Baseline estimated glomerular filtration rate (eGFR)(mL/min)HealthyModerate Renal ImpairmentSevere Renal ImpairmentTotal
Mean100.758 ± 9.980244.292 ± 8.836122.875 ± 5.072955.975 ± 34.6775
08

Study locations

1 site
  • Research by Design ( Site 0001)
    Chicago, Illinois 60643, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jan 2025, 7 months.

Results were first posted in Feb 2026, 1 year after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 6, 2024
StartActual
Jun 20, 2024
Primary completionActual
Jan 31, 2025
CompletionActual
Jan 31, 2025
Results first posted
Feb 17, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06295796
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Jun 20, 2024
Primary completion
Jan 31, 2025
Completion
Jan 31, 2025
Results posted
Feb 17, 2026
Last update
Feb 17, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion